Home > Haematology > EHA 2021 > Myeloma and Myelofibrosis > ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By
Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece
Conference
EHA 2021
Trial
Phase 3, ANDROMEDA
Addition of daratumumab to standard-of-care treatment in patients with amyloid light-chain (AL) amyloidosis showed superior efficacy to standard-of-care treatment alone, according to updated results of the ANDROMEDA trial. Based on these results, this combination therapy has become the first approved therapy for AL amyloidosis. Systemic AL amyloidosis is a rare plasma cell disease characterised by the deposition of insoluble amyloid fibrils causing organ dysfunction and death. Patients have a poor prognosis: about 30% die within the first year of diagnosis and the 4-year survival rate is 54% [1]. Median overall survival in patients with Mayo stage IIIB at baseline is 2.5–3.5 months [2]. Prof. Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) presented updated results of the ongoing, open-label, randomised, phase 3 ANDROMEDA study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on